
-
What Will The Incoming Trump Administration Mean For Drug Patents?11/21/2024
Megan Chacon, a principal at Fish & Richardson and a member of the firm’s life sciences industry team, answers questions about what a second Trump administration could mean for biopharmaceutical IP and drug patents.
-
CEO Panel Talks IRA Impact At Galien Forum11/14/2024
A panel of biopharmaceutical leaders convened at the Galien Forum discussed the impacts of the Inflation Reduction Act so far, and what's likely to come in the year ahead.
-
A Bioethicist Weighs In On Obesity Drugs10/31/2024
Anne Zimmerman, editor-in-chief of the Columbia University online journal, Voices in Bioethics discusses her concerns over the use of GLP-1 weight loss drugs in the U.S.
-
Where Are They Now? Ironwood Pharmaceuticals10/31/2024
Ironwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its founder and mission. But Peter Hecht, Ironwood's former CEO, who now leads Tisento Therapeutics, has practiced what he preached.
-
Companies To Watch: Spinogenix10/18/2024
Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, glaucoma, and Fragile X syndrome.
-
Annovis Bio: Against The Grain In Alzheimer's Disease10/1/2024
From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s independent-minded approach to neurodegenerative disease could shake up the treatment landscape.
-
New Leadership At The Cancer Research Institute9/27/2024
Alicia Zhou, Ph.D., the incoming CEO at the Cancer Research Institute, talks about her plans and approach to moving a 70-year old cancer research nonprofit into the future.
-
Where Are They Now? Carisma Therapeutics9/22/2024
In three years, Carisma Therapeutics has gone public, entered a broad collaboration with Moderna, and ceased development of its original CAR-Macrophage candidate, in favor of CAR-Monocyte therapies. Carisma expects to release CT-0525 Phase 1 data by the end of 2024.
-
A Systems Approach To Parkinson's Disease8/30/2024
New research into Parkinson's disease is strengthening the connection between an unhealthy gut and brain disorders.